Document is current
Any future updates will be listed below
-
Authors
Juarez, Maria G.
O’Rourke, Sara M.
Dzimianski, John V.
Gagnon, Delia
Penunuri, Gabriel
Serrão, Vitor H. B.
Corbett-Detig, Russell B.
Kauvar, Lawrence M.
DuBois, Rebecca M.
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (T32 GM133391)
Cota Robles Fellowship
National Human Genome Research Institute (T32 HG012344)
National Institute of Allergy and Infectious Diseases (R01 AI166066)
- License Information
-
More Information
Article History
Received: 3 November 2024
Accepted: 3 March 2025
First Online: 13 March 2025
Declarations
:
: Lawrence Kauvar is a founder, officer and shareholder of Trellis Bioscience, Inc., which is preparing TRL3D3 (mAb 3D3) for clinical trials. Rebecca DuBois is a shareholder of Trellis Bioscience, Inc. Lawrence Kauvar and Rebecca DuBois are inventors on patent application US20240150414A1. Maria Juarez, Sara O’Rourke, John Dzimianski, Delia Gagnon, Gabriel Penunuri, Vitor Serrão, and Russel Corbett-Detig declare that they have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the results and/or discussion reported in this paper.
